三星医疗（601567）1月14日主力资金净卖出143.46万元

Core Viewpoint - Samsung Medical (601567) experienced a decline in stock price, closing at 24.5 yuan on January 14, 2026, with a trading volume of 306,300 hands and a total transaction amount of 760 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Samsung Medical reported a main revenue of 11.08 billion yuan, an increase of 6.19% year-on-year [3] - The net profit attributable to shareholders was 1.528 billion yuan, a decrease of 15.85% year-on-year [3] - The net profit after deducting non-recurring items was 1.28 billion yuan, down 26.81% year-on-year [3] - In Q3 2025, the company’s single-quarter main revenue was 3.108 billion yuan, a decline of 9.56% year-on-year [3] - The single-quarter net profit attributable to shareholders was 298 million yuan, a decrease of 55.22% year-on-year [3] - The single-quarter net profit after deducting non-recurring items was 144 million yuan, down 78.54% year-on-year [3] - The company’s debt ratio stood at 47.57%, with investment income of 179 million yuan and financial expenses of -109 million yuan [3] - The gross profit margin was reported at 28.46% [3] Group 2: Market Activity - On January 14, 2026, the net outflow of main funds was 1.4346 million yuan, accounting for 0.19% of the total transaction amount [1] - Retail investors saw a net inflow of 22.827 million yuan, representing 3.01% of the total transaction amount [1] - Over the past five days, the financing buy amounted to 82.3109 million yuan, while financing repayment was 76.1522 million yuan, resulting in a net financing increase of 6.1587 million yuan [2] - The total financing and securities balance was reported at 383 million yuan [2] Group 3: Analyst Ratings - In the last 90 days, six institutions have given buy ratings for Samsung Medical, with an average target price of 30.16 yuan [4]